Financial Services
Live Price
Offline$76.06
+0.00% today
Window Change
+38.46%
Window
Nov 19, 2025 → Jun 23, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 45 bars · Nov 19, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BB Biotech AG (BBAGF) is a Financial Services stock with a market cap of $2.49B. The stock last traded around $76.06 and up 38.5% across the available one-year price window (Nov 19, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +425.9%, EPS growth of +665.2%, a dividend yield of 5.0%. What stands out right now is revenue +425.9%, EPS +665.2%, free cash flow +1.5% with operating margin 171.9% and ROIC -1.7%. The dividend matters to the case here, with a current yield around 5.0%. Stock Foundry combines BBAGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BBAGF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BBAGF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BBAGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$699.2M
+276.9% YoY
FY Net Income
$691.2M
+270.7% YoY
Free Cash Flow
$262.4M
+376.9% YoY
Revenue Growth
+425.9%
EPS Growth
+665.2%
Gross Margin
100.0%
Net Margin
1063.9%
Income statement
CHF
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 112M | -194M | -350M | -395M | 699M |
| Gross Profit | 112M | -200M | -351M | -396M | 699M |
| Operating Income | 84M | -207M | -39M | -53M | 700M |
| EBITDA | 80M | -201M | -351M | -405M | 691M |
| Net Income | 76M | -207M | -358M | -405M | 691M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 458K | 501K | 2M | 3M | 7M |
| Total Assets | 2.4B | 2.6B | 3.1B | 3.6B | 4.0B |
| Total Liabilities | 121M | 314M | 363M | 355M | 63M |
| Shareholder Equity | 2.3B | 2.3B | 2.7B | 3.3B | 3.9B |
| Total Debt | 118M | 305M | 363M | 355M | 63M |
| Net Debt | 117M | -501K | 361M | 352M | 56M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
262M
+376.9% YoY
Capital Expenditures
0
Free Cash Flow
262M
+376.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
171.9%
Net Margin
1063.9%
ROE
-12.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.